Pharmacokinetics and Safety/Tolerability Profile of CKD-379
Type II Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type II Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Between 19 aged and 50 aged in healthy adult
- 50.0kg ≤ Body weight ≤ 90.0kg and 18.0kg/m2 ≤ body mass index (BMI) ≤ 27.0kg/m2
Exclusion Criteria:
- Have clinical significant medical history or disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, digestive system, urinary system, endocrine system(Type I or Type II Diabetes Mellitus, diabetic ketoacidosis ect.), hematological system, cardiovascular system(heart failure, Torsades de pointes etc.), mental illness
- Have clinical significant medical history or disease that urinary tract infection or genital infection including urosepsis, pyelonephritis
- Have a gastrointestinal disease(Crohn's disease, ulcer ect.) history that can effect drug absorption or surgery
- Those who are pregnant or breastfeeding
- Those who are deemed inappropriate to participate in clinical trial by investigators
Sites / Locations
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Sequence 1
Sequence 2
Sequence 3
Sequence 4
Sequence 5
Sequence 6
Period 1: Test drug(CKD-379 I) Period 2: Test drug(CKD-379 II) Period 3: Reference drug(D759+D745+D150)
Period 1: Test drug(CKD-379 I) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 II)
Period 1: Test drug(CKD-379 II) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 I)
Period 1: Test drug(CKD-379 II) Period 2: Test drug(CKD-379 I) Period 3: Reference drug(D759+D745+D150)
Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 I) Period 3: Test drug(CKD-379 II)
Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 II) Period 3: Test drug(CKD-379 I)